My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 441

    1.

    Narrative review: Fabry disease.

    Clarke JT.

    Ann Intern Med. 2007 Mar 20;146(6):425-33. Review.PMID: 17371887 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Early therapeutic intervention in females with Fabry disease?

    Hughes DA.

    Acta Paediatr Suppl. 2008 Apr;97(457):41-7. Review.PMID: 18339187 [PubMed - indexed for MEDLINE]Related articles

    3.

    Twenty-four-month alpha-galactosidase A replacement therapy in Fabry disease has only minimal effects on symptoms and cardiovascular parameters.

    Koskenvuo JW, Hartiala JJ, Nuutila P, Kalliokoski R, Viikari JS, Engblom E, Penttinen M, Knuuti J, Mononen I, Kantola IM.

    J Inherit Metab Dis. 2008 Jun;31(3):432-41. Epub 2008 May 23.PMID: 18509742 [PubMed - indexed for MEDLINE]Related articles

    4.

    Fabry disease: cardiac manifestations and therapeutic options.

    Pierre-Louis B, Kumar A, Frishman WH.

    Cardiol Rev. 2009 Jan-Feb;17(1):31-5. Review.PMID: 19092368 [PubMed - indexed for MEDLINE]Related articles

    5.

    [Fabry disease. An interdisciplinary challenge]

    Cybulla M, Neumann HP.

    Dtsch Med Wochenschr. 2007 Oct;132(43):2271-7. Review. German. PMID: 17940933 [PubMed - indexed for MEDLINE]Related articles

    6.

    Fabry disease: molecular genetics of the inherited nephropathy.

    Desnick RJ, Astrin KH, Bishop DF.

    Adv Nephrol Necker Hosp. 1989;18:113-27. Review.PMID: 2564247 [PubMed - indexed for MEDLINE]Related articles

    7.

    Enzyme replacement therapy of Fabry disease.

    Clarke JT, Iwanochko RM.

    Mol Neurobiol. 2005 Aug;32(1):43-50. Review.PMID: 16077182 [PubMed - indexed for MEDLINE]Related articles

    8.

    Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy.

    Thurberg BL, Rennke H, Colvin RB, Dikman S, Gordon RE, Collins AB, Desnick RJ, O'Callaghan M.

    Kidney Int. 2002 Dec;62(6):1933-46.PMID: 12427118 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey).

    Hoffmann B, Garcia de Lorenzo A, Mehta A, Beck M, Widmer U, Ricci R; FOS European Investigators.

    J Med Genet. 2005 Mar;42(3):247-52.PMID: 15744039 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    [Fabry disease--a provocation for pediatrics]

    Hoffmann B, Mayatepek E.

    Klin Padiatr. 2006 Jan-Feb;218(1):38-40. German. PMID: 16432775 [PubMed - indexed for MEDLINE]Related articles

    11.

    Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy.

    Breunig F, Wanner C.

    J Nephrol. 2008 Jan-Feb;21(1):32-7. Review.PMID: 18264934 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Clinical features of and recent advances in therapy for Fabry disease.

    Brady RO, Schiffmann R.

    JAMA. 2000 Dec 6;284(21):2771-5. Erratum in: JAMA 2001 Jan 10;285(2):169. PMID: 11105184 [PubMed - indexed for MEDLINE]Related articles

    13.

    Clinical spectrum of Anderson Fabry disease in a Romanian family.

    Tudor A, Muşat A, Doscan A, Bari M, Zapucioiu C, Urdea E, Cochior D, Peţa D.

    Rom J Intern Med. 2006;44(2):201-10.PMID: 17236300 [PubMed - indexed for MEDLINE]Related articles

    14.

    Treatment of neutral glycosphingolipid lysosomal storage diseases via inhibition of the ABC drug transporter, MDR1. Cyclosporin A can lower serum and liver globotriaosyl ceramide levels in the Fabry mouse model.

    Mattocks M, Bagovich M, De Rosa M, Bond S, Binnington B, Rasaiah VI, Medin J, Lingwood C.

    FEBS J. 2006 May;273(9):2064-75.PMID: 16724420 [PubMed - indexed for MEDLINE]Related articles

    15.

    [Fabry disease in Spain: first analysis of the response to enzyme replacement therapy]

    Rivera Gallego A, López Rodríguez M, Barbado Hernández FJ, Barba Romero MA, García de Lorenzo Y Mateos A, Pintos Morelle G; Grupo Español de Estudio de Fabry Outcome Survey.

    Med Clin (Barc). 2006 Oct 7;127(13):481-4. Spanish. PMID: 17043001 [PubMed - indexed for MEDLINE]Related articles

    16.

    Fabry disease: focus on cardiac manifestations and molecular mechanisms.

    Perrot A, Osterziel KJ, Beck M, Dietz R, Kampmann C.

    Herz. 2002 Nov;27(7):699-702.PMID: 12439642 [PubMed - indexed for MEDLINE]Related articles

    17.

    [Neurological manifestations of Fabry disease]

    Mendióroz M, Fernández-Cadenas I, Montaner J.

    Rev Neurol. 2006 Dec 16-31;43(12):739-45. Review. Spanish. PMID: 17160925 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer.

    Ziegler RJ, Yew NS, Li C, Cherry M, Berthelette P, Romanczuk H, Ioannou YA, Zeidner KM, Desnick RJ, Cheng SH.

    Hum Gene Ther. 1999 Jul 1;10(10):1667-82.PMID: 10428212 [PubMed - indexed for MEDLINE]Related articles

    19.

    Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease.

    Schiffmann R, Murray GJ, Treco D, Daniel P, Sellos-Moura M, Myers M, Quirk JM, Zirzow GC, Borowski M, Loveday K, Anderson T, Gillespie F, Oliver KL, Jeffries NO, Doo E, Liang TJ, Kreps C, Gunter K, Frei K, Crutchfield K, Selden RF, Brady RO.

    Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):365-70.PMID: 10618424 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults.

    Ortiz A, Oliveira JP, Wanner C, Brenner BM, Waldek S, Warnock DG.

    Nat Clin Pract Nephrol. 2008 Jun;4(6):327-36. Epub 2008 Apr 22.PMID: 18431378 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity